October 18, 2018

New ASPIRE Award to Enable Adoptive Cell Therapy

The Mark Foundation for Cancer Research has announced Michelle Krogsgaard, PhD of New York University School of Medicine as its latest ASPIRE Award recipient.

An Associate Professor in the Department of Pathology, Dr. Krogsgaard and her collaborators propose the development of a humanized transgenic mouse model by building artificial human chromosomes that will provide a robust and broadly applicable system for T-cell Receptor (TCR) identification for clinical adoptive cell strategies.

Dr. Krogsgaard’s collaborators on this project include New York University colleagues Jef Boeke, PhD, Director of the Institute for Systems Genetics and Professor in the Department of Biochemistry and Molecular Pharmacology and Jeffrey Weber, MD, PhD, Deputy Director of the Perlmutter Cancer Center.

This project holds the promise of increased efficacy and safety of Adoptive Cell Transfer (ACT) as a personalized immunotherapy for cancer patients. Neoantigen-specific T-cell receptors identified through the use of this new model will enable the expanded use of neoantigen-targeting T-cells in ACT.

The ASPIRE Awards (Accelerating Scientific Platforms and Innovative Research) are designed to enable innovative approaches to solving high-impact problems in cancer research that tend to fall outside the scope of other funding opportunities.

Learn more about The Mark Foundation’s ASPIRE Awards here.